Specify a stock or a cryptocurrency in the search bar to get a summary
Alpha Cognition Inc.
ACOGFAlpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada. Address: 750 West Pender Street, Vancouver, BC, Canada, V6C 2T8
Analytics
WallStreet Target Price
66.17 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ACOGF
Dividend Analytics ACOGF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ACOGF
Stock Valuation ACOGF
Financials ACOGF
Results | 2019 | Dynamics |